Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

<p>Raw data provided by Nanostring bioinformatic team</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Yeh Wang (14964041) (author)
Andere auteurs:	Peng Huang (14964044) (author), Brant G. Wang (14964047) (author), Tricia Murdock (14964050) (author), Leslie Cope (14964053) (author), Fang-Chi Hsu (14964056) (author), Tian-Li Wang (14964059) (author), Ie-Ming Shih (14964062) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Risk Factors Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Cancer Prevention Biomarkers Early detection biomarkers Cancer Interception Biomarkers and intervention Carcinogenesis Tumor initiation and promotion Epigenetics DNA methylation Gynecological Cancers Ovarian cancer Tumor Evolution
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
door: Yeh Wang (14964041)
Gepubliceerd in: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
door: Raphaël Leman (17314506)
Gepubliceerd in: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
door: Nicola S. Meagher (15048462)
Gepubliceerd in: (2025)

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
door: Christopher J. Gibson (15907642)
Gepubliceerd in: (2025)

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
door: Christopher J. Gibson (15907642)
Gepubliceerd in: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
door: Katleen Janssens (15053356)
Gepubliceerd in: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
door: Félix Blanc-Durand (15049400)
Gepubliceerd in: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
door: Jun Wang (15051911)
Gepubliceerd in: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
door: Sanna Pikkusaari (15055802)
Gepubliceerd in: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
door: Sanna Pikkusaari (15055802)
Gepubliceerd in: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
door: Colin S. Wood (15293247)
Gepubliceerd in: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
door: Athanasios Bikas (16006076)
Gepubliceerd in: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
door: Daniel S. Green (15047598)
Gepubliceerd in: (2025)

Supplementary file 3: Supplementary Tables. from circFNDC3B Accelerates Vasculature Formation and Metastasis in Oral Squamous Cell Carcinoma
door: Xiang Li (15386727)
Gepubliceerd in: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
door: Laura Privitera (16015972)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_m6sna8h1skd1kbpd68uj1b6ooe